HeartSciences Inc. (HSCS)
NASDAQ: HSCS · Real-Time Price · USD
2.670
+0.030 (1.14%)
Nov 21, 2024, 12:15 PM EST - Market open

Company Description

HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to enhance its clinical utility.

It is developing artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction and conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis.

The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024.

HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.

HeartSciences Inc.
HeartSciences logo
Country United States
Founded 2007
IPO Date Jun 15, 2022
Industry Medical Devices
Sector Healthcare
Employees 15
CEO Andrew Simpson

Contact Details

Address:
550 Reserve Street, Suite 360
Southlake, Texas 76092
United States
Phone 682-237-7781
Website heartsciences.com

Stock Details

Ticker Symbol HSCS
Exchange NASDAQ
Fiscal Year May - April
Reporting Currency USD
IPO Price $4.25
CIK Code 0001468492
CUSIP Number 42254E104
ISIN Number US42254E1047
Employer ID 26-1344466
SIC Code 3842

Key Executives

Name Position
Andrew Simpson Chief Executive Officer, President and Chairman of the Board of Directors
Danielle Watson Chief Financial Officer and Treasurer
Mark T. Hilz Chief Operating Officer, Secretary and Director

Latest SEC Filings

Date Type Title
Nov 8, 2024 8-K Current Report
Oct 21, 2024 8-K/A [Amend] Current report
Oct 18, 2024 8-K Current Report
Sep 27, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Sep 26, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Sep 18, 2024 DEF 14A Other definitive proxy statements
Sep 12, 2024 8-K Current Report
Sep 12, 2024 10-Q Quarterly Report
Sep 10, 2024 8-K Current Report
Aug 21, 2024 8-K Current Report